Incannex healthcare announces positive topline results from pharmacokinetics (pk) study of ihl-42x, an oral combination medicine for the treatment of obstructive sleep apnea

New york and melbourne, australia, jan. 23, 2025 (globe newswire) -- incannex healthcare inc. (nasdaq: ixhl), (incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines, today announced positive topline results from a completed pharmacokinetics (pk) and safety study of ihl-42x, a novel, oral fixed-dose combination of acetazolamide and dronabinol for the treatment of obstructive sleep apnea (osa).
IXHL Ratings Summary
IXHL Quant Ranking